Special Issue

Gut Microbial Dysbiosis in Disease Pathogenesis

Message from the Guest Editors

Gut microbiota is considered an organ of the human system due to multiple functional roles. This is an adaptive and dynamic system that reflects the health status and can be a potential biomarker in the future. Microbiota plays important roles in training the immune system and various metabolic pathways. The role of microbial dysbiosis in causing diseases is clear from the increase in allergic and autoimmune diseases observed in developing countries as seen in developed countries. This is attributed to changes in the diet and lifestyle that are considered to affect the microbiota. With affordable next-generation sequencing, microbiome studies are conducted at small and large scales to explore various human diseases. These studies mostly profile dysbiosis. Microbiome studies in the future are required to establish the mechanistic role of microbial dysbiosis in various disease pathogeneses. This Special Issue invites original research and review articles that expand our knowledge on the role of dysbiosis in disease pathogenesis. Studies conducted in animal models and human subjects will be accepted for submission.

Guest Editors

Dr. Pugazhendhi Srinivasan

School of Medicine, University of Kansas Medical Center, Kansas City, KS, USA

Dr. Nanda Kumar Navalpur Shanmugam

Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA

Deadline for manuscript submissions

closed (31 January 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/145096

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).